Blog
RSS FeedPosted by Michael Wonder on 19 May 2019
Australians want cheaper medicines quicker
20 May 2019 - Just last week, an 18-year-old woman with a rare cancer was staring down the barrel of ...
Posted by Michael Wonder on 18 May 2019
NICE recommends Revlimid as multiple myeloma alternative
17 May 2019 - NICE has recommended Revlimid (lenalidomide), a drug that helps to support the immune system to fight ...
Posted by Michael Wonder on 17 May 2019
Celgene receives European Commission approvals for Revlimid (lenalidomide) and Imnovid (pomalidomide)-based triplet combination regimens for patients with multiple myeloma
16 May 2019 - The European Commission has approved two of Celgene’s IMiD based combination regimens. ...
Posted by Michael Wonder on 17 May 2019
Health technology assessment challenges in oncology: 20 years of Value in Health
16 May 2019 - Oncology treatments have changed from chemotherapies to targeted therapies and more recently immuno-oncology. ...
Posted by Michael Wonder on 15 May 2019
Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma
15 May 2019 - There are no serious disadvantages in terms of overall survival. ...
Posted by Michael Wonder on 15 May 2019
Novartis gets approval to sell Kymriah in Japan for $306,000
15 May 2019 - A Japanese government panel approved on Wednesday a price of 33.5 million yen ($305,800) for Novartis’ cancer ...
Posted by Michael Wonder on 15 May 2019
AbbVie announces US FDA approval of Venclexta (venetoclax) as a chemotherapy-free combination regimen for previously untreated chronic lymphocytic leukaemia patients
15 May 2019 - FDA reviewed the submission under the real-time oncology review pilot program. ...
Posted by Michael Wonder on 15 May 2019
FDA approves Bavencio (avelumab) plus axitinib combination for patients with advanced renal cell carcinoma
14 May 2019 - Phase III study showed combination significantly lowered risk of disease progression or death by 31% and extended ...
Posted by Michael Wonder on 14 May 2019
Cellectar receives FDA fast track designation for CLR 131 in relapsed or refractory multiple myeloma
13 May 2019 - Designation could accelerate CLR 131 development and underscores the need for new treatments. ...
Posted by Michael Wonder on 14 May 2019
Celgene Corporation announces Pomalyst granted breakthrough therapy designation from FDA for HIV positive and negative Kaposi sarcoma
13 May 2019 - Celgene plans to submit sNDA by end of 2019. ...
Posted by Michael Wonder on 13 May 2019
Japan health ministry orders Ono Pharmaceutical to add warning to Opdivo cancer drug after death
10 May 2019 - The health ministry said Thursday that a patient taking the cancer drug Opdivo has died and ...
Posted by Michael Wonder on 13 May 2019
New cancer drugs approved for NHS use in Scotland
13 May 2019 - The Scottish Medicines Consortium accepted the use of new medicines to treat patients with breast and skin ...
Posted by Michael Wonder on 13 May 2019
Lilly's Cyramza (ramucirumab) becomes first FDA approved biomarker-driven therapy in patients with hepatocellular carcinoma
13 May 2019 - This new indication - the fifth FDA approval for Cyramza in an advanced or metastatic cancer - ...
Posted by Michael Wonder on 10 May 2019
Speed up cancer funding, ALP told
11 May 2019 - The head of Australian drug company Specialised Therapeutics, Carlo Montagner, has warned that Bill Shorten’s cancer ...
Posted by Michael Wonder on 09 May 2019
Cancer specialists ‘won’t increase’ fees under Labor plan
9 May 2019 - Australia’s cancer doctors have rejected Scott Morrison’s claims they will charge patients higher fees under Labor’s ...